| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:10746942 | IVR | 400 mg/kg | 400 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg | 200 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| PMID:10825674 | IVR | 400 mg/kg | 400 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | - | No significant effects observed | - | |
| IVR | 300 mg/kg | - | No significant effects observed | - | |
| IVR | 200 mg/kg | - | No significant effects observed | - | |
| PMID:10860870 | IVR | 12.5 mg/kg/day | - | No significant effects observed | - |
| IVR | 50 mg/kg/day | - | No significant effects observed | - | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Uterine hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Alters hypothalamic-pituitary-ovarian axis | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Endometrial hyperplasia | Reproductive endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | - | No significant effects observed | - | |
| PMID:10906426 | IVR | 12.5 mg/kg/day | 12.5 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations |
| IVR | 12.5 mg/kg/day | 12.5 mg/kg/day | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| PMID:11259270 | IVR | 100 mg/kg | 100 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Cognitive impairment | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased LH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Altered lordosis | Developmental endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased prolactin levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Decreased FSH levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:11275424 | IVR | 62.5 mg/kg | 62.5 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations |
| IVR | 125 mg/kg | 125 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 31.3 mg/kg | 31.3 mg/kg | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 15.6 mg/kg | - | No significant effects observed | - | |
| IVR | 31.3 mg/kg | 31.3 mg/kg | Affects implantation | Reproductive endocrine-mediated perturbations | |
| PMID:11936222 | IVTH | 0.00000001 - 0.001 M | 0.000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | - | No significant effects observed | - | |
| PMID:12051553 | IVR | 100 mg/kg | 100 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 100 mg/kg | 100 mg/kg | Affects differentiation process | Developmental endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| PMID:12127004 | IVR | 25 - 3000 mg/kg | 125 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 25 - 3000 mg/kg | 750 - 3000 mg/kg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 25 - 3000 mg/kg | 3000 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 25 - 3000 mg/kg | 3000 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 25 - 3000 mg/kg | 500 - 700 mg/kg | Decreased spleen weights | Immunological endocrine-mediated perturbations | |
| PMID:14654251 | IVR | 200 mg/kg/day | 200 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:14689164 | IVR | 200 mg/kg | 200 mg/kg | Affects uterine function | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg | 200 mg/kg | Alteration in vaginal morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg | 200 mg/kg | Affects uterine morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | - | No significant effects observed | - | |
| IVR | 50 mg/kg | - | No significant effects observed | - | |
| PMID:14763995 | IVR | 40 mg/kg | 40 mg/kg | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| PMID:15219628 | IVR | 200 mg/kg/day | 200 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:15509668 | IVR | 250 mg/kg | 250 mg/kg | Affects uterine contraction | Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/kg | 500 mg/kg | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg | - | No significant effects observed | - | |
| PMID:17011747 | IVR | 600 mg/kg/day | 600 mg/kg/day | Affects differentiation process | Developmental endocrine-mediated perturbations |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects innate immunity | Immunological endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Induce tumor progression | Endocrine-mediated cancer | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects uterine function | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Alters estrogen-responsive genes | Reproductive endocrine-mediated perturbations | |
| IVR | 600 mg/kg/day | 600 mg/kg/day | Uterotrophic effect | Reproductive endocrine-mediated perturbations | |
| PMID:17033158 | IVR | 10 mg | 10 mg | Decreased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg | 10 mg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:17365578 | IVR | 200 mg/kg | 200 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations |
| IVR | 600 mg/kg | 600 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 400 mg/kg | 400 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:17696135 | IVR | 2 mg/kg | 2 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations |
| IVR | 2 mg/kg | 2 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 2 mg/kg | 2 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| PMID:19145065 | IVR | 100 mg/kg | - | No significant effects observed | - |
| IVR | 10 mg/kg | - | No significant effects observed | - | |
| IVR | 600 mg/kg | 600 mg/kg | Increase in Growth Hormone (GH) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 600 mg/kg | 600 mg/kg | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| PMID:20197112 | IVTH | 0.00000000001 - 0.0000001 M | 0.000000001 - 0.0000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| PMID:23219593 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:23664861 | IVR | 100 mg/kg/day | 100 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects neuronal differentiation | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 10 mg/kg/day | 10 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:24278580 | IVTH | 0.000000001 - 0.00001 M | 0.000000001 - 0.00001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| PMID:24698786 | IVR | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00000001 - 0.0001 M | 0.00000001 - 0.0001 M | Alteration in the levels of cAMP | Metabolic endocrine-mediated perturbations | |
| PMID:25324873 | IVR | 10 mg/kg/day | - | No significant effects observed | - |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Affects uterine contraction | Reproductive endocrine-mediated perturbations | |
| PMID:27145024 | IVTH | 0.000001 M | 0.000001 M | Induce cancer metastasis | Endocrine-mediated cancer |
| PMID:29561242 | IVR | 40 mg/kg | 40 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations |
| IVR | 40 mg/kg | 40 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects cytokine signaling | Immunological endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| PMID:30061528 | IVR | 100 mg/kg/day | 100 mg/kg/day | Affects implantation | Reproductive endocrine-mediated perturbations |
| PMID:31201952 | IVTH | 0.00001 M | 0.00001 M | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000005 M | 0.000005 M | Pregnancy complications | Reproductive endocrine-mediated perturbations | |
| PMID:31911191 | IVR | 360 mg/kg | 360 mg/kg | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations |
| IVR | 360 mg/kg | 360 mg/kg | Affects tryptophan metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 360 mg/kg | 360 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 360 mg/kg | 360 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 120 mg/kg | 120 mg/kg | Affects tryptophan metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 120 mg/kg | 120 mg/kg | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 120 mg/kg | 120 mg/kg | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 120 mg/kg | 120 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 40 mg/kg | 40 mg/kg | Increased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 360 mg/kg | 360 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:33294128 | IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Abnormal proliferation of neuronal cells | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Altered cell cycle in neurons | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Affects spatial memory | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Decreased brain weights | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Induce neuronal apoptosis | Neurological endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg/day | 1 - 5 mg/kg/day | Cognitive impairment | Neurological endocrine-mediated perturbations | |
| PMID:38997027 | IVTH | 0.000001 - 0.00005 M | 0.000001 - 0.00005 M | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVTH | 0.000001 - 0.00005 M | 0.000001 - 0.00005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:39471617 | IVR | 5 mg/kg/day | 5 mg/kg/day | Changes in brain morphology | Neurological endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects neuronal density | Neurological endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Causes inflammation | Immunological endocrine-mediated perturbations | |
| PMID:9241039 | IVR | 20 mg | 20 mg | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations |
| IVR | 80 mg | 80 mg | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.